7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS

      research-article
      1 , 2 , 19 , 1 , 3 , 1 , 1 , 1 , 4 , 19 , 1 , 5 , 19 , 6 , 7 , 19 , 8 , 19 , 9 , 19 , 10 , 19 , 5 , 19 , 11 , 19 , 12 , 19 , 8 , 19 , 12 , 19 , 13 , 14 , 19 , 15 , 19 , 16 , 19 , 17 , 19 , 11 , 19 , 6 , 19 , 4 , 1 , 4 , 19 , 1 , 3 , 6 , 7 , 19 , 1 , 2 , 19 , 1 , 18 , 19 ,
      Scientific Reports
      Nature Publishing Group UK
      Respiratory tract diseases, Iron

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Levels of iron and iron-related proteins including ferritin are higher in the lung tissue and lavage fluid of individuals with chronic obstructive pulmonary disease (COPD), when compared to healthy controls. Whether more iron in the extracellular milieu of the lung associates with distinct clinical phenotypes of COPD, including increased exacerbation susceptibility, is unknown. We measured iron and ferritin levels in the bronchoalveolar lavage fluid (BALF) of participants enrolled in the SubPopulations and InteRmediate Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-study (n = 195). BALF Iron parameters were compared to systemic markers of iron availability and tested for association with FEV 1 % predicted and exacerbation frequency. Exacerbations were modelled using a zero-inflated negative binomial model using age, sex, smoking, and FEV 1 % predicted as clinical covariates. BALF iron and ferritin were higher in participants with COPD and in smokers without COPD when compared to non-smoker control participants but did not correlate with systemic iron markers. BALF ferritin and iron were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferritin and iron conveying a 24% and 2-fold increase in exacerbation risk, respectively. Similar associations were not observed with plasma ferritin. Increased airway iron levels may be representative of a distinct pathobiological phenomenon that results in more frequent COPD exacerbation events, contributing to disease progression in these individuals.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          The natural history of chronic airflow obstruction.

          A prospective epidemiological study of the early stages of the development of chronic obstructive pulmonary disease was performed on London working men. The findings showed that forced expiratory volume in one second (FEV1) falls gradually over a lifetime, but in most non-smokers and many smokers clinically significant airflow obstruction never develops. In susceptible people, however, smoking causes irreversible obstructive changes. If a susceptible smoker stops smoking he will not recover his lung function, but the average further rates of loss of FEV1 will revert to normal. Therefore, severe or fatal obstructive lung disease could be prevented by screening smokers' lung function in early middle age if those with reduced function could be induced to stop smoking. Infective processes and chronic mucus hypersecretion do not cause chronic airflow obstruction to progress more rapidly. There are thus two largely unrelated disease processes, chronic airflow obstruction and the hypersecretory disorder (including infective processes).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.

            Currently, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) of less than 0.70 as assessed by spirometry after bronchodilator use. However, many smokers who do not meet this definition have respiratory symptoms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hyperferritinemia and inflammation.

              Understanding of ferritin biology has traditionally centered on its role in iron storage and homeostasis, with low ferritin levels indicative of deficiency and high levels indicative of primary or secondary hemochromatosis. However, further work has shown that iron, redox biology and inflammation are inexorably linked. During infection, increased ferritin levels represent an important host defense mechanism that deprives bacterial growth of iron and protect immune cell function. It may also be protective, limiting the production of free radicals and mediating immunomodulation. Additionally, hyperferritinemia is a key acute-phase reactant, used by clinicians as an indication for therapeutic intervention, aimed at controlling inflammation in high risk patients. One school of thought maintains that hyperferritinemia is an 'innocent bystander' biomarker of uncontrolled inflammation that can be used to gauge effectiveness of intervention. Other schools of thought maintain that ferritin induction could be a protective negative regulatory loop. Others maintain that ferritin is a key mediator of immune dysregulation, especially in extreme hyperferritinemia, via direct immune suppressive and pro-inflammatory effects. There is a clear need for further investigation of the role of ferritin in uncontrolled inflammatory conditions both as a biomarker and mediator of disease because its occurrence identifies patients with high mortality risk and its resolution predicts their improved survival.
                Bookmark

                Author and article information

                Contributors
                szc2009@med.cornell.edu
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                29 June 2020
                29 June 2020
                2020
                : 10
                : 10562
                Affiliations
                [1 ]ISNI 000000041936877X, GRID grid.5386.8, Joan and Sanford I. Weill Department of Medicine, Division of Pulmonary and Critical Care Medicine, , Weill Cornell Medicine, ; New York, USA
                [2 ]ISNI 0000 0000 8499 1112, GRID grid.413734.6, New York-Presbyterian Hospital, ; New York, New York USA
                [3 ]ISNI 000000041936877X, GRID grid.5386.8, Department of Population Health Sciences, Division of Biostatistics, , Weill Cornell Medicine, ; New York, New York USA
                [4 ]ISNI 000000041936877X, GRID grid.5386.8, Department of Genetic Medicine, , Weill Cornell Medicine, ; New York, New York USA
                [5 ]ISNI 0000 0001 1034 1720, GRID grid.410711.2, University of North Carolina Marsico Lung Institute, ; Chapel Hill, North Carolina USA
                [6 ]ISNI 0000 0000 9081 2336, GRID grid.412590.b, Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, , University of Michigan Health System, ; Ann Arbor, Michigan USA
                [7 ]Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan USA
                [8 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, University of California at San Francisco, ; San Francisco, California USA
                [9 ]ISNI 0000 0001 2185 3318, GRID grid.241167.7, Wake Forest School of Medicine, ; Winston-Salem, North Carolina USA
                [10 ]Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama UK
                [11 ]ISNI 0000 0001 2171 9311, GRID grid.21107.35, Johns Hopkins University School of Medicine, ; Baltimore, Maryland USA
                [12 ]ISNI 0000 0000 9142 8600, GRID grid.413083.d, Division of Pulmonary and Critical Care Medicine, , University of California Los Angeles Medical Center, ; Los Angeles, California USA
                [13 ]ISNI 0000 0001 0703 675X, GRID grid.430503.1, University of Colorado School of Medicine, ; Aurora, Colorado USA
                [14 ]ISNI 0000 0004 0396 0728, GRID grid.240341.0, National Jewish Health, ; Denver, Colorado USA
                [15 ]ISNI 0000 0004 1936 8294, GRID grid.214572.7, Division of Pulmonary and Critical Care, , University of Iowa, ; Iowa City, Iowa USA
                [16 ]ISNI 0000 0001 2248 3398, GRID grid.264727.2, Department of Pulmonary & Critical Care Medicine, , Temple University, ; Philadelphia, Pennsylvania USA
                [17 ]GRID grid.413886.0, Section of Pulmonary and Critical Care Medicine, Salt Lake City Department of Veterans Affairs Medical Center, ; Salt Lake City, Utah USA
                [18 ]ISNI 0000 0004 1936 9705, GRID grid.8217.c, School of Medicine, , Trinity Biomedical Sciences Institute and Tallaght University Hospital, Trinity College Dublin, ; Trinity, Ireland
                [19 ]ISNI 0000000122483208, GRID grid.10698.36, SPIROMICS investigators, Collaborative Studies Coordinating Center, Department of Biostatistics Gillings School of Global Public Health, , University of North Carolina at Chapel Hill 123 W. Franklin Street Suite 450, ; Chapel Hill, NC 27516 USA
                Article
                67047
                10.1038/s41598-020-67047-w
                7324559
                32601308
                b9c8b878-4df0-499a-8a69-b11e30734b6a
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 12 December 2019
                : 2 June 2020
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                respiratory tract diseases,iron
                Uncategorized
                respiratory tract diseases, iron

                Comments

                Comment on this article